253 related articles for article (PubMed ID: 32161197)
1. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.
Luukkonen PK; Tukiainen T; Juuti A; Sammalkorpi H; Haridas PAN; Niemelä O; Arola J; Orho-Melander M; Hakkarainen A; Kovanen PT; Dwivedi O; Groop L; Hodson L; Gastaldelli A; Hyötyläinen T; Orešič M; Yki-Järvinen H
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161197
[TBL] [Abstract][Full Text] [Related]
2. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Wang P; Wu CX; Li Y; Shen N
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
[TBL] [Abstract][Full Text] [Related]
3. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
[TBL] [Abstract][Full Text] [Related]
4. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.
Pirola CJ; Garaycoechea M; Flichman D; Arrese M; San Martino J; Gazzi C; Castaño GO; Sookoian S
J Lipid Res; 2019 Jan; 60(1):176-185. PubMed ID: 30323112
[TBL] [Abstract][Full Text] [Related]
5. The rs72613567: TA Variant in the Hydroxysteroid 17-beta Dehydrogenase 13 Gene Reduces Liver Damage in Obese Children.
Di Sessa A; Umano GR; Cirillo G; Marzuillo P; Arienzo MR; Pedullà M; Miraglia Del Giudice E
J Pediatr Gastroenterol Nutr; 2020 Mar; 70(3):371-374. PubMed ID: 31789772
[TBL] [Abstract][Full Text] [Related]
6. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
[TBL] [Abstract][Full Text] [Related]
7. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice.
Su W; Wu S; Yang Y; Guo Y; Zhang H; Su J; Chen L; Mao Z; Lan R; Cao R; Wang C; Xu H; Zhang C; Li S; Gao M; Chen X; Zheng Z; Wang B; Liu Y; Liu Z; Wang Z; Liu B; Fan X; Zhang X; Guan Y
Nat Commun; 2022 Nov; 13(1):6577. PubMed ID: 36323699
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of
Luukkonen PK; Sakuma I; Gaspar RC; Mooring M; Nasiri A; Kahn M; Zhang XM; Zhang D; Sammalkorpi H; Penttilä AK; Orho-Melander M; Arola J; Juuti A; Zhang X; Yimlamai D; Yki-Järvinen H; Petersen KF; Shulman GI
Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2217543120. PubMed ID: 36669104
[TBL] [Abstract][Full Text] [Related]
10. A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Bayard Q; Gustot T; Deviere J; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Hepatology; 2019 Jul; 70(1):231-240. PubMed ID: 30908678
[TBL] [Abstract][Full Text] [Related]
11. Impact of a Loss-of-Function Variant in
Gil-Gómez A; Rojas Á; García-Lozano MR; Muñoz-Hernández R; Gallego-Durán R; Maya-Miles D; Montero-Vallejo R; Gato S; Gallego J; Francés R; Soriano G; Ampuero J; Romero-Gómez M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233142
[TBL] [Abstract][Full Text] [Related]
12. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
Gellert-Kristensen H; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
Hepatology; 2020 Jan; 71(1):56-66. PubMed ID: 31155741
[TBL] [Abstract][Full Text] [Related]
13. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.
Luukkonen PK; Qadri S; Ahlholm N; Porthan K; Männistö V; Sammalkorpi H; Penttilä AK; Hakkarainen A; Lehtimäki TE; Gaggini M; Gastaldelli A; Ala-Korpela M; Orho-Melander M; Arola J; Juuti A; Pihlajamäki J; Hodson L; Yki-Järvinen H
J Hepatol; 2022 Mar; 76(3):526-535. PubMed ID: 34710482
[TBL] [Abstract][Full Text] [Related]
14. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.
Scheiner B; Stättermayer AF; Schwabl P; Bucsics T; Paternostro R; Bauer D; Simbrunner B; Schmidt R; Marculescu R; Ferlitsch A; Peck-Radosavljevic M; Pinter M; Trauner M; Reiberger T; Ferenci P; Mandorfer M
Liver Int; 2020 Feb; 40(2):393-404. PubMed ID: 31967400
[TBL] [Abstract][Full Text] [Related]
15. Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.
Hudert CA; Adams LA; Alisi A; Anstee QM; Crudele A; Draijer LG; Furse S; Hengstler JG; Jenkins B; Karnebeek K; Kelly DA; Koot BG; Koulman A; Meierhofer D; Melton PE; Mori TA; Snowden SG; van Mourik I; Vreugdenhil A; Wiegand S; Mann JP;
Hepatol Commun; 2022 Aug; 6(8):1934-1948. PubMed ID: 35411667
[TBL] [Abstract][Full Text] [Related]
16. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.
Abul-Husn NS; Cheng X; Li AH; Xin Y; Schurmann C; Stevis P; Liu Y; Kozlitina J; Stender S; Wood GC; Stepanchick AN; Still MD; McCarthy S; O'Dushlaine C; Packer JS; Balasubramanian S; Gosalia N; Esopi D; Kim SY; Mukherjee S; Lopez AE; Fuller ED; Penn J; Chu X; Luo JZ; Mirshahi UL; Carey DJ; Still CD; Feldman MD; Small A; Damrauer SM; Rader DJ; Zambrowicz B; Olson W; Murphy AJ; Borecki IB; Shuldiner AR; Reid JG; Overton JD; Yancopoulos GD; Hobbs HH; Cohen JC; Gottesman O; Teslovich TM; Baras A; Mirshahi T; Gromada J; Dewey FE
N Engl J Med; 2018 Mar; 378(12):1096-1106. PubMed ID: 29562163
[TBL] [Abstract][Full Text] [Related]
17. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
[TBL] [Abstract][Full Text] [Related]
18. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
Tang S; Zhang J; Mei TT; Zhang WY; Zheng SJ; Yu HB
BMC Gastroenterol; 2021 Dec; 21(1):490. PubMed ID: 34930143
[TBL] [Abstract][Full Text] [Related]
19. Role of Patatin-Like Phospholipase Domain-Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes.
Zaharia OP; Strassburger K; Knebel B; Kupriyanova Y; Karusheva Y; Wolkersdorfer M; Bódis K; Markgraf DF; Burkart V; Hwang JH; Kotzka J; Al-Hasani H; Szendroedi J; Roden M;
Diabetes Care; 2020 Sep; 43(9):2161-2168. PubMed ID: 32910776
[TBL] [Abstract][Full Text] [Related]
20. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
